Abstract: The invention relates to tunicamycin analogues which are compounds according to Formula (I), or pharmaceutically acceptable salts thereof, (I) Wherein [Base] and R1 to R9 are as defined herein. The tunicamycin analogues are useful in the prevention or treatment of bacterial infection, in particular of tuberculosis.

Abstract: The invention relates to tunicamycin analogues which are compounds according to Formula (I), or pharmaceutically acceptable salts thereof, (I) Wherein [Base] and R1 to R9 are as defined herein. The tunicamycin analogues are useful in the prevention or treatment of bacterial infection, in particular of tuberculosis.

Abstract: The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.

Abstract: An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of Lewis A or Lewis B or its mimetics. Lewis A and Lewis B and its mimetics are also provided for use in the therapeutic treatment of inflammatory diseases, autoimmune diseases and cancer.

Abstract: The invention relates to a conjugate which comprises an MRI contrast agent component comprising a nanoparticle, which nanoparticle comprises a metal or a metal compound, and a hypoxia targeting moiety which is conjugated to the MRI contrast agent component, especially wherein said nanoparticle comprises iron oxide and a biocompatible coating and wherein said hypoxia targeting moiety is a nitroimidazole. Also provided is the use of a said conjugate in a method of imaging a subject, a method of de-testing hypoxia, and a method of evaluating the activity of a pharmaceutical. Said conjugate is also of use in diagnosis.

Abstract: The invention relates to methods for selectively converting a cysteine residue in a peptide or protein to the dehydroalanine (Dha) residue. The method also works on selenocysteine and substituted cysteine and selenocysteine residues, resulting in the Dha residue which may be converted to any natural or unnatural amino acid residue desired without the alteration of the remainder of the peptide or protein. The invention also allows ligation of a desired peptide at any point rather than at a point where there should be a naturally occurring cysteine, thereby allowing native chemical ligation to be used in the synthesis of peptides that do not contain cysteine. The methodology allows for the synthesis of very large peptides.

Abstract: A method of detecting the structural elements within a scene sensed by at least one sensor within a locale, the method comprising: a) capturing data from the sensor, which data provides a first representation of the sensed scene at the current time; b) generating a second representation of the sensed scene where the second representation is generated from a prior model of the locale; and c) comparing the first and second representations with one another to determine which parts of the first representation represent structural elements of the locale.

Abstract: An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of Lewis A or Lewis B or its mimetics. Lewis A and Lewis B and its mimetics are also provided for use in the therapeutic treatment of inflammatory diseases, autoimmune diseases and cancer.

Abstract: The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.

Abstract: The invention provides multimeric particle comprising metal-containing particles covalently bonded to one another by linker groups wherein at least some of said linker groups are cleavable. The invention further provides a contrast agent comprising said multimeric particles, along with a method of improving contrast of an image using said contrast agent.

Abstract: Modified viral particles wherein the viral particles, typically adenoviral particles, are modified by glycosylation and the use of the modified viral particles to deliver heterologous nucleic acid to cells. Also disclosed are pharmaceutical compositions comprising the same and method of treatment using the same.

Abstract: Methods and reagents for the formation of disulfide bonds, particularly in proteins, peptides and amino acids. The methods and reagents are particularly useful for the controlled glycosylation of proteins, peptides and amino acids. The methods utilize thiosulfonate or selenenylsulfide compounds as reagents or intermediates. Some proteins and peptides comprising selenenyl-sulfide groups also form part of the invention.

Abstract: The invention provides an isolated formate dehydrogenase (FDH) polypeptide specific for NADP+ and an isolated FDH polypeptide having an adenine ribose recognition loop comprising a first large amino acid and a second amino acid, wherein the first and second amino acid are arranged in space to allow the second amino acid to bond with a phosphate group. Also provided is a variant of an BAD+ specific FDH polypeptide, wherein the adenine ribose recognition loop has been mutated at least one position to alter the three dimensional polypeptide structure of the adenine ribose recognition loop to allow a phosphate group to be recognised. The polypeptides of the invention can be used in the conversion of NADP+ to NADP or in the conversion of BAD+ to NASH.

Abstract: A method for the modification of an amino acid, protein or peptide is disclosed. The method comprises reacting a carbon-carbon double bond-containing compound with an amino acid, a protein or a peptide containing an allyl sulfide group in the presence of a catalyst which promotes olefin metathesis, to form a modified amino acid, protein or peptide. Preferred carbon-carbon double bond-containing compounds include carbohydrates.

Abstract: The present invention relates to methods for glycosylating a protein in which the protein is modified to include an alkyne and/or an azide group. The invention further relates to a protein glycosylated by these methods.

Abstract: The invention provides multimeric particle comprising metal-containing particles covalently bonded to one another by linker groups wherein at least some of said linker groups are cleavable. The invention further provides a contrast agent comprising said multimeric particles, along with a method of improving contrast of an image using said contrast agent.

Abstract: Novel FDH enzymes are provided herein, including novel NADPH-specific and NADH-specific FDH enzymes. Additionally, methods are provided utilizing these novel enzymes in catalytic systems for in situ regeneration of NADPH or NADH. Further aspects of the invention relate to the definition and use of crystal structures of these novel enzymes.

Abstract: A process for the preparation of a thiosaccharide represented by Saccharide-S-H wherein Saccharide comprises at least 4 sugar units, comprises subjecting a corresponding compound of the formula (P)Saccharide-S-(P) wherein (P) represents an O- or S-protecting group(s), to Birch reduction.

Abstract: The invention provides a conjugate comprising an iron containing colloidal particle, the particle being conjugated to one or more sugar targeting moieties. The conjugate is useful as a contrast agent in medical imaging, particularly in magnetic resonance imaging (MRI). The agents of the present invention may cross the blood brain barrier and so may be particularly useful in the monitoring or diagnosis of conditions affecting the brain.

Abstract: A method of producing an ester linked carbohydrate-peptide conjugate is provided comprising: (a) providing a vinyl ester amino acid group, and (b) reacting the vinyl ester amino acid with a carbohydrate acyl acceptor in the presence of an enzyme, to produce thereby an ester-linked carbohydrate-peptide conjugate. Also provided are ester linked carbohydrate-peptide conjugates obtainable by such methods.